Hoving, Jan W. http://orcid.org/0000-0003-3310-3973
van Voorst, Henk http://orcid.org/0000-0002-2647-3557
Peerlings, Daan
Daems, Jasper D. http://orcid.org/0000-0002-6245-8020
Koopman, Miou S. http://orcid.org/0000-0003-4709-0130
Wouters, Anke http://orcid.org/0000-0001-5229-2699
Kappelhof, Manon http://orcid.org/0000-0001-5250-8955
LeCouffe, Natalie E. http://orcid.org/0000-0002-6668-8755
Treurniet, Kilian M. http://orcid.org/0000-0003-3227-3620
Bruggeman, Agnetha A. E. http://orcid.org/0000-0002-6873-2545
Rinkel, Leon A. http://orcid.org/0000-0002-0291-8515
van den Wijngaard, Ido R. http://orcid.org/0000-0002-3734-6086
Coutinho, Jonathan M. http://orcid.org/0000-0002-8284-982X
van der Lugt, Aad http://orcid.org/0000-0002-6159-2228
Marquering, Henk A. http://orcid.org/0000-0002-1414-6313
Roos, Yvo B. W. E. M. http://orcid.org/0000-0001-9205-5882
Majoie, Charles B. L. M. http://orcid.org/0000-0002-7600-9568
Emmer, Bart J. http://orcid.org/0000-0001-8462-4037
,
Article History
Received: 7 December 2022
Accepted: 1 March 2023
First Online: 8 March 2023
Declarations
:
: BJE reports grants from LtC (ZonMW and TKI-PPP of Health Holland) outside the submitted work. CBLMM reports grants from CVON/Dutch Heart Foundation and Stryker (related) and TWIN Foundation, European Commission and Health Evaluation Netherlands, outside the submitted work, all paid to institution, and is (minority interest) shareholder of Nicolab. YBWEM reports grants from the Dutch Heart Foundation, Brain Foundation Netherlands, and Stryker outside the submitted work (paid to institution) and is shareholder of Nicolab. AL reports grants from Dutch Heart Foundation, the Brain Foundation Netherlands, Health-Holland, Stryker, Medtronic, Penumbra, Cerenovus, Siemens Healthineers, Philips Healthcare, and GE Healthcare, all paid to institution. HAM is co-founder and shareholder of Nicolab. All other contributors report no conflicts of interest.
: The MR CLEAN-NO IV trial protocol was approved by Dutch (MEC-2017-368), Belgian (ID-RCB: 2018-A00764-51), and French (B322201939935, 19/20/987) ethical committees and the research board of each participating center. The final versions of the trial protocol and statistical analysis plan are both available at ExternalRef removed. The MR CLEAN-NO IV trial was conducted in accordance with the revised Helsinki guidelines.
: Patients or representatives of patients included in the MR CLEAN-NO IV trial provided written informed deferred consent.